Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $56.40 Consensus Price Target from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been assigned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $56.40.

Several equities analysts have recently weighed in on the company. Ascendiant Capital Markets reduced their price objective on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th.

Hedge Funds Weigh In On Plus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PSTV. L1 Global Manager Pty Ltd purchased a new stake in Plus Therapeutics during the 4th quarter worth $1,167,000. Geode Capital Management LLC lifted its stake in shares of Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the fourth quarter worth about $525,000. Virtu Financial LLC purchased a new stake in shares of Plus Therapeutics in the fourth quarter worth about $254,000. Finally, State Street Corp boosted its position in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after buying an additional 127,000 shares during the period. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Stock Down 0.8%

PSTV stock opened at $3.83 on Monday. The company has a market cap of $26.37 million, a price-to-earnings ratio of -1.67 and a beta of 1.40. The business has a fifty day simple moving average of $4.30 and a 200-day simple moving average of $5.54. Plus Therapeutics has a 52 week low of $2.90 and a 52 week high of $23.42.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. As a group, analysts expect that Plus Therapeutics will post -3.76 earnings per share for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.